The pharmaceuticals division currently generates $2 billion in annual sales — two-thirds of that in the U.S. market. The product division of the company does $9.6 billion in annual sales. Some of the drug unit’s products include Exalgo, an extended release opioid, and Pennsaid, a topical anti-inflammatory. Covidien said that entire process could take up to 18 months.
Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
Related Articles on Pain Management:
Dr. Danzhu Guo and Dr. Thomas Wilkins Recognized by the National Committee for Quality Assurance Back Pain Recognition Program
New York City Launches Task Force to Combat Prescription Drug Problem
Opioid Abuse Linked to Mood and Anxiety Disorders
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
